In order to provide an effective target for the personalized treatment of prostate cancer, we identified drug metabolism-related core genes which related to drug metabolism, drug sensitivities, and related treatment outcomes in multi-omics, such as CYP1A1, CYP2B6, CYP3A4, UGT1A8, UGT2B11, UGT2B17, UGT2B7, GAS5, XIST, SNHG6. This evidence concerns the gene UGT2B17 and prostate cancer.